More positive data from AGN's phase 2 study!
"More positive data" from AGN's Phase 2 study: https://www.youtube.com/watch?v=-aSxBqqp4Vo&ab_channel=Proactive
In the topline data, Ifenprodil is much more effective at reducing cough with the geometric mean 24-hour cough counts being reduced by 32.0% at 4 weeks and 39.5% at 12 weeks. Plus, the geometric mean awake cough counts were reduced by 30.2% at 4 weeks and 37.4% at 12 weeks.
The statistical improvement and statistical significance with such a small study size is quite significant and is an optimistic sign for the IPF phase 2b study going forward.
Keep an eye out for the full data to be released later in August.